Autoimmune encephalitis with CASPR2 antibody: A case series and updated literature review
International Immunopharmacology · 2025-09 · 162 · 115200
DOI: 10.1016/j.intimp.2025.115200 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2025-09. Verfasst von Xiaoke Wu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Neuroscience Centre, The First Hospital of Jilin University, Changchun, China. Hauptthemen laut MEDLINE: Nerve Tissue Proteins, Encephalitis, Autoantibodies, Membrane Proteins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Natural Science Foundation of Henan Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
OBJECTIVE: Contactin-associated protein-like 2 (CASPR2) encephalitis is an under-recognized and relatively rare type of autoimmune encephalitis (AE). Here, we investigated the clinical manifestations and outcomes in patients with CASPR2 encephalitis. METHODS: The data of patients with CASPR2 encephalitis were collected retrospectively, and their clinical features were analyzed. Additionally, clinical features and prognoses of CASPR2 encephalitis in previously reported studies were summarized and analyzed. RESULTS: Fifteen patients (median age: 52 years; age range: 10-81 years, nine were male) were studied. The main clinical manifestations studied included limbic system symptoms (73.3 %), seizures (53.3 %), mental-behavioral anomalies (20 %), peripheral nerve hyperexcitability (PNH) symptoms (20 %), paresthesia of limbs (20 %), fasciculation (13.3 %), ataxia (13.3 %), impaired consciousness (13.3 %), Morvan syndrome (13.3 %), cerebellar symptoms (13.3 %), as well as high tumor markers (26.7 %). The values of abnormal signals in brain magnetic resonance imaging (MRI) and abnormal electroencephalogram (EEG) were 33.3 % and 40 %, respectively. Thirteen (86.7 %) patients received first-line immunotherapy, 12 (75 %) showed complete recovery at the last follow-up (18 months) on the modified ranking scale (mRS = 0), but two (13.3 %) patients experienced relapses. In addition, we investigated the clinical data of 440 patients with CASPR2 encephalitis available in the literature and included 25 relevant publications, which involved 315 men. Furthermore, 37 patients developed tumors during the disease or recurrence. At the follow-up, 212 patients displayed a mRS score of ≤2, and the mRS scores of 50 patients ranged from 3 to 6. In total, 43 patients displayed disease relapse during discharge until the last follow-up, and immunotherapy improved their symptoms. Nevertheless, 14 patients died during the follow-up. We have summarized here the included cases in the light of relevant previous studies, and the associated results conformed to those from previous studies. CONCLUSIONS: Patients with CASPR2 encephalitis exhibited diverse clinical features and presented several symptoms, including limbic system symptoms, PNH symptoms, Morvan syndrome, and cerebellar symptoms. Most of the patients in the present study responded well to immunotherapy and exhibited a lower chance of recurrence in the short term. The review of the relevant literature on CASPR2 encephalitis from the viewpoint of clinical characteristics and prognoses of CASPR2 encephalitis further deepened our understanding of the disease. Thus, recurrence and concomitant tumors in patients with CASPR2 encephalitis should be continuously monitored.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Neuroscience Centre, The First Hospital of Jilin University, Changchun, China.
- Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Electronic address: zhf840317@163.com.
- Department of Neurology, Neuroscience Centre, The First Hospital of Jilin University, Changchun, China. Electronic address: jluneu@163.com.
Förderung
- Natural Science Foundation of Henan Province
- National Natural Science Foundation of China
Zitieren
APA
Wu, X., Shi, M., Zhang, H., & Fang, S. (2025). Autoimmune encephalitis with CASPR2 antibody: A case series and updated literature review. International Immunopharmacology, 162, 115200. https://doi.org/10.1016/j.intimp.2025.115200
Vancouver
Wu X, Shi M, Zhang H, Fang S. Autoimmune encephalitis with CASPR2 antibody: A case series and updated literature review. International Immunopharmacology. 2025;162:115200. doi:10.1016/j.intimp.2025.115200
BibTeX
@article{Wu2025,
author = {Wu, Xiaoke and Shi, Mengmeng and Zhang, Haifeng and Fang, Shaokuan},
title = {Autoimmune encephalitis with CASPR2 antibody: A case series and updated literature review},
journal = {International Immunopharmacology},
year = {2025},
volume = {162},
pages = {115200},
doi = {10.1016/j.intimp.2025.115200}
}
EUVIMED